Tokyo Tape
Sign in
← PHC Holdings

Quarterly report · Q3

6523.TEDINET S100SW3M
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥256.7bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥89.9bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥356.4bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥265.1bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥94.5bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income−¥5.1bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income−¥9.3bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥21.4bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥10.9bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax−¥13.8bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax−¥10.7bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥179m2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥7.4bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥4.0bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)−¥11.2bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥8.7bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥3.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥3.4bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.2bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income−¥11.2bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income−¥8.7bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥3.6bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥2.2bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥541.0bnat 2023-12-31Cons.Assets IFRS
Total assets¥561.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥569.9bnat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥416.7bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥422.7bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥124.3bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥138.8bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥138.8bnat 2022-12-31Cons.Equity IFRS
Net assets / equity¥136.1bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥124.7bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥138.0bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥137.9bnat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥43.9bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.9bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥59.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥95.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥28.5bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥21.4bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥6.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥17.1bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥17.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥11.3bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥31.1bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥40.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥32.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-88.72023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥-69.072023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥-25.842022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥27.332022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥17.692022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-88.72023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-69.072023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥-25.842022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥27.072022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥17.532022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio23.0%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.6%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.2%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-12-31¥1.8bn
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-12-31¥1.8bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥7.3bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue2023-04-01 → 2023-12-31¥80.3bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue external2023-04-01 → 2023-12-31¥80.3bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentsegment profit2023-04-01 → 2023-12-31¥8.8bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2023-04-01 → 2023-12-31¥79.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2023-04-01 → 2023-12-31¥79.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2023-04-01 → 2023-12-31¥4.9bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue2023-04-01 → 2023-12-31¥95.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue external2023-04-01 → 2023-12-31¥95.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentsegment profit2023-04-01 → 2023-12-31−¥11.6bn
—segment totalrevenue2023-04-01 → 2023-12-31¥254.9bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥254.9bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥2.1bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31¥1.8bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥1.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥13.0bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue2022-04-01 → 2022-12-31¥83.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentrevenue external2022-04-01 → 2022-12-31¥83.7bn
jpcrp040300-q3r_E36976-000Diabetes Managementreportable segmentsegment profit2022-04-01 → 2022-12-31¥19.7bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2022-04-01 → 2022-12-31¥80.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2022-04-01 → 2022-12-31¥80.4bn
jpcrp040300-q3r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2022-04-01 → 2022-12-31¥6.3bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue2022-04-01 → 2022-12-31¥99.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentrevenue external2022-04-01 → 2022-12-31¥99.2bn
jpcrp040300-q3r_E36976-000Healthcare Solutionsreportable segmentsegment profit2022-04-01 → 2022-12-31¥8.5bn
—segment totalrevenue2022-04-01 → 2022-12-31¥263.3bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥263.3bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥34.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 875
ItemContextValueUnit
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember1760000000JPY
Revenue from external customers IFRSCurrentYTDDuration256683000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember80343000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember95184000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember79394000000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember254923000000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember1760000000JPY
Revenue IFRSCurrentYTDDuration256683000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember8822000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember-11618000000JPY
Operating profit loss IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember4927000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember2131000000JPY
Operating profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember-7259000000JPY
Operating profit loss IFRSCurrentYTDDuration-5128000000JPY
Finance income IFRSCurrentYTDDuration552000000JPY
Finance costs IFRSCurrentYTDDuration9202000000JPY
Profit loss before tax IFRSCurrentYTDDuration-13778000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember5329000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember8139000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember6486000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_ReportableSegmentsMember19956000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration_ReconcilingItemsMember502000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration20458000000JPY
Impairment losses pl IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiabetesManagementReportableSegmentMember－JPY
Impairment losses pl IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000HealthcareSolutionsReportableSegmentMember13983000000JPY
Impairment losses pl IFRSCurrentYTDDuration_jpcrp040300-q3r_E36976-000DiagnosticsAndLifeSciencesReportableSegmentMember2151000000JPY
Impairment losses pl IFRSCurrentYTDDuration_ReportableSegmentsMember16135000000JPY
Impairment losses pl IFRSCurrentYTDDuration_ReconcilingItemsMember0JPY
Impairment losses pl IFRSCurrentYTDDuration16135000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-02-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第11期第３四半期（自　2023年10月１日　至　2023年12月31日）
Company name cover pageFilingDateInstant
Original text (Japanese)ＰＨＣホールディングス株式会社
Company name in english cover pageFilingDateInstantPHC Holdings Corporation
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長CEO　　宮﨑　正次
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区西新橋二丁目38番５号
Telephone number address of registered headquarter cover pageFilingDateInstant03-6695-9938
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)常務執行役員　最高財務責任者（CFO）　フレデリック・ライデンバック
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区西新橋二丁目38番５号
Telephone number nearest place of contact cover pageFilingDateInstant03-6695-9938
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)常務執行役員　最高財務責任者（CFO）　フレデリック・ライデンバック
Place for public inspection cover page (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass